Drug profile · INN
maribavir
LIVTENCITY
maribavir (LIVTENCITY) is a phosphotransferase pul97 inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — maribavir
- US status
- approved
- Class
- Antiinfectives for systemic use (J05)
- Route
- ORAL
- Patents
- 3
- Programs
- 12
- Data quality
- 0.89
Quick answer
maribavir (LIVTENCITY) is a phosphotransferase pul97 inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Phosphotransferase pUL97 inhibitor
Primary target: Serine/threonine protein kinase UL97
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is maribavir?
maribavir (LIVTENCITY) is a phosphotransferase pul97 inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for maribavir?
LIVTENCITY is a marketed brand name for maribavir. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of maribavir?
maribavir has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.